Company intelligence / Profile preview

Phenocell

Grasse, Provence-Alpes-Côte d’Azur, France

Ownership: Private
Development stage: Other

Overview

Phenocell has established robust human iPSC-derived cellular models for dermo-cosmetic and ophthalmology drug discovery, including widely used models for age-related macular degeneration and skin biology; no public clinical results as services focus on preclinical research [1][2][3].

Therapeutic areas: DermatologyOphthalmology
Modalities: Induced pluripotent stem cell derived therapyCell therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Phenocell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phenocell.

Explore the full profile